MET Exon 14 Variants in Non-Small Cell Lung Carcinoma: Prevalence, Clinicopathologic and Molecular Features
نویسندگان
چکیده
Somatic MET exon 14 skipping mutations (MET ex14) are targetable driver for non-small cell lung cancer (NSCLC), responsive to inhibitors. Objective: This study seeks further characterize the clinicopathologic features and mutational profile of ex14 variant NSCLC. Design: Retrospective review all tested Testing selected BRAF, EGFR, HER2, KRAS, was performed using a clinically validated NGS assay, followed by MiSeq sequencing. Variants were classified as significant (Tier1/2) or variants uncertain significance (VUS) per 2017 AMP/ASCO/CAP Joint Consensus Guidelines. PD-L1 expression assessed immunohistochemistry. Results: Of 2296 NSCLCs between 2017-7/2019, present in 44 (1.9%). A total 32 skipping, while other 12 missense (3) VUS (9). nine VUS, five adjacent canonical splice site likely impact splicing. Four cases had concomitant mutations. 35 with known clinical staging, stage 1–2 = 20 (57%), 3 (9%), 4 (34%). 19 resected NSCLSs, histological types growth pattern included 7 lepidic pattern-predominant. high percentage tumors positive PD-L1, >50% trends higher more advanced disease. Conclusions: Most identified our cohort (73%) skipping. The prevalence is 1.9%, large has lower less aggressive pathologic features.
منابع مشابه
MET Exon 14 Skipping in Non-Small Cell Lung Cancer.
BACKGROUND Non-small cell lung cancers (NSCLCs) harboring specific genetic alterations can be highly sensitive to targeted therapies. MATERIALS AND METHODS We performed a targeted rearrangement assay on 54 NSCLCs across all stages that were from patients who were never smokers and did not have driver mutations. Because MET exon 14 skipping was the most frequent alteration found, we surveyed t...
متن کاملMET exon 14 skipping defines a unique molecular class of non-small cell lung cancer
PURPOSE Recurrent MET exon 14 splicing has been revealed in lung cancers and is a promising therapeutic target. Because we have limited knowledge about the natural history of MET mutant tumors, the current study was aiming to determine the clinical and pathological characteristics in non-small cell lung cancers (NSCLC). RESULTS Twenty-three patients (1.3%) were positive for MET exon 14 skippi...
متن کاملMatrix metalloproteinase-9 (MMP-9) Expression in Non-Small Cell Lung Carcinoma and Its Association with Clinicopathologic Factors
Background & Objective: Matrix metalloproteinases-9 (MMP-9) is one of the most important enzymes to breakdown extracellular matrix which plays a major role in tumor invasion and metastasis. This study aimed to determine tumor MMP-9 expression in non-small-cell lung carcinoma (NSCLC) and whethe...
متن کاملMET Amplification and Exon 14 Splice Site Mutation Define Unique Molecular Subgroups of Non-Small Cell Lung Carcinoma with Poor Prognosis.
PURPOSE Activation of MET oncogene as the result of amplification or activation mutation represents an emerging molecular target for cancer treatment. We comprehensively studied MET alterations and the clinicopathologic correlations in a large cohort of treatment-naïve non-small cell lung carcinoma (NSCLC). EXPERIMENTAL DESIGN Six hundred eighty-seven NSCLCs were tested for MET exon 14 splici...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of molecular pathology
سال: 2023
ISSN: ['2673-5261']
DOI: https://doi.org/10.3390/jmp4010006